IL146241A0 - VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY - Google Patents
VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAYInfo
- Publication number
- IL146241A0 IL146241A0 IL14624100A IL14624100A IL146241A0 IL 146241 A0 IL146241 A0 IL 146241A0 IL 14624100 A IL14624100 A IL 14624100A IL 14624100 A IL14624100 A IL 14624100A IL 146241 A0 IL146241 A0 IL 146241A0
- Authority
- IL
- Israel
- Prior art keywords
- tnf
- traf2
- variants
- inhibitor
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13194099P | 1999-04-30 | 1999-04-30 | |
PCT/US2000/009178 WO2000066737A1 (en) | 1999-04-30 | 2000-04-06 | VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY |
Publications (1)
Publication Number | Publication Date |
---|---|
IL146241A0 true IL146241A0 (en) | 2002-07-25 |
Family
ID=22451697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14624100A IL146241A0 (en) | 1999-04-30 | 2000-04-06 | VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1180140A4 (en) |
JP (1) | JP2002542826A (en) |
KR (1) | KR20020012194A (en) |
CN (1) | CN1309830C (en) |
AU (2) | AU4076800A (en) |
CA (1) | CA2372803A1 (en) |
HU (1) | HUP0200946A3 (en) |
IL (1) | IL146241A0 (en) |
MX (1) | MXPA01011107A (en) |
WO (1) | WO2000066737A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0003458D0 (en) * | 2000-02-16 | 2000-04-05 | Secr Defence Brit | Rubber structure & method of making the same |
CA2449487A1 (en) * | 2001-06-07 | 2002-12-12 | Pu Xia | Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity |
US20050180974A1 (en) * | 2003-10-24 | 2005-08-18 | Medtronic, Inc. | Extracellular TNF inhibitors for treating CNS disorders |
WO2022152856A1 (en) * | 2021-01-15 | 2022-07-21 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Methods and compositions for treating ischaemia in a subject |
CN114672550B (en) * | 2022-05-05 | 2023-11-17 | 青岛大学 | Atherosclerosis biomarker and inhibitor and application thereof |
-
2000
- 2000-04-06 MX MXPA01011107A patent/MXPA01011107A/en unknown
- 2000-04-06 WO PCT/US2000/009178 patent/WO2000066737A1/en not_active Application Discontinuation
- 2000-04-06 HU HU0200946A patent/HUP0200946A3/en unknown
- 2000-04-06 CA CA002372803A patent/CA2372803A1/en not_active Abandoned
- 2000-04-06 JP JP2000615761A patent/JP2002542826A/en not_active Withdrawn
- 2000-04-06 IL IL14624100A patent/IL146241A0/en unknown
- 2000-04-06 EP EP00920190A patent/EP1180140A4/en not_active Withdrawn
- 2000-04-06 CN CNB008082790A patent/CN1309830C/en not_active Expired - Fee Related
- 2000-04-06 AU AU40768/00A patent/AU4076800A/en not_active Abandoned
- 2000-04-06 KR KR1020017013914A patent/KR20020012194A/en not_active Application Discontinuation
-
2005
- 2005-08-17 AU AU2005203749A patent/AU2005203749A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2372803A1 (en) | 2000-11-09 |
HUP0200946A3 (en) | 2005-06-28 |
EP1180140A4 (en) | 2004-08-25 |
AU4076800A (en) | 2000-11-17 |
WO2000066737A1 (en) | 2000-11-09 |
JP2002542826A (en) | 2002-12-17 |
AU2005203749A1 (en) | 2005-09-15 |
EP1180140A1 (en) | 2002-02-20 |
KR20020012194A (en) | 2002-02-15 |
CN1309830C (en) | 2007-04-11 |
HUP0200946A2 (en) | 2002-07-29 |
CN1353754A (en) | 2002-06-12 |
MXPA01011107A (en) | 2002-08-09 |
WO2000066737A9 (en) | 2002-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL145778A0 (en) | Methods and compositions for inhibiting the function of polynucleotide sequences | |
HK1215265A1 (en) | Treatment of tnf alpha related disorders tnf | |
EP1406875A4 (en) | N-heterocyclic inhibitors of tnf-alpha expression | |
IL149118A0 (en) | Inhibitors of neuraminidases | |
EP1165084A4 (en) | Inhibitors of prenyl-protein transferases | |
AU3408801A (en) | Tnf-alpha inhibitors | |
PL344586A1 (en) | Stabilization of compositions containing ace inhibitors using magnesium oxide | |
HUP0201846A2 (en) | Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them | |
GB9930659D0 (en) | Inhibitors of complement activation | |
AU5969101A (en) | Modulators of tnf-alpha signaling | |
GB9923866D0 (en) | Correlation of signalling messages | |
IL146241A0 (en) | VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY | |
HUP0102363A3 (en) | Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway | |
EP1158982A4 (en) | Inhibitors of prenyl-protein transferase | |
PT1090664E (en) | Discharge of floating sludge | |
HUP0102259A3 (en) | Methods of inhibiting corrosion using isomers of chloro-methylbenzotriazole | |
EP1165013A4 (en) | Inhibitors of prenyl-protein transferase | |
EP1409463A4 (en) | N-heterocyclic inhibitors of tnf-alpha expression | |
AU2003299137A8 (en) | Inhibition of metallo-beta-lactamase | |
AU2003271988A8 (en) | Modulation of tgfbeta-like signalling pathways | |
EP1158983A4 (en) | Inhibitors of prenyl-protein transferase | |
AU8281398A (en) | Methods of inhibiting or enhancing the tgfbeta-smad signaling pathway | |
GB9900148D0 (en) | Inhibitors of prenyl-protein transferase | |
IT1308103B1 (en) | PROCEDURE AND COMPOSITIONS FOR THE PURIFICATION OF WATERS CONTAINING RESIDUAL ACRYLIC AND EPOXYACRYLIC POLYMERS | |
TW551676U (en) | Connector of video signal line |